Results 111 to 120 of about 626,622 (390)

Normal pregnancy is associated with an increase in thrombin generation from the very early stages of the first trimester [PDF]

, 2017
Background: Pregnancy is a hypercoagulable state associated with an increased risk of venous thrombosis, which begins during the first trimester, but the exact time of onset is unknown.
Bagot, C.N., Freeman, D.J., Jordan, F., Leishman, E., Onyiaodike, C.C.   +4 more
core   +1 more source

Venous Thromboembolism in COVID-19

Thrombosis and Haemostasis, 2020
The coronavirus disease 2019 (COVID-19) is our latest pandemic, preceded by the H1N1 swine flu in 2009, which lasted approximately 19 months. One of the special characteristics of COVID-19 is the propensity to cause venous thromboembolism (VTE ...
S. Schulman, Yu Hu, S. Konstantinides
semanticscholar   +1 more source

Left Ventricular Apical Thrombus in Apical Hypertrophic Cardiomyopathy Without Aneurysm or Arrhythmia: A Case Report

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Apical hypertrophic cardiomyopathy (ApHCM) is a rare variant of hypertrophic cardiomyopathy, typically associated with a benign course. However, complications such as ventricular arrhythmias, apical aneurysms, and thrombus formation may occur. Left ventricular (LV) thrombus is an unusual finding in ApHCM, especially in patients with preserved ...
Ibrahim Antoun, Jeffrey Khoo, Sanjay S. Bhandari   +2 more
wiley   +1 more source

Infection and venous thromboembolism in patients undergoing colorectal surgery: what is the relationship? [PDF]

, 2014
BACKGROUND: There is evidence demonstrating an association between infection and venous thromboembolism. We recently identified this association in the postoperative setting; however, the temporal relationship between infection and venous thromboembolism
Efron, Jonathan E., Gearhart, Susan L., Haut, Elliott R., Hui, Xuan, Lau, Brandyn D., Monn, M. Francesca, Streiff, Michael, Wick, Elizabeth C.   +7 more
core   +1 more source

Predicting Recurrence after a First Unprovoked Venous Thromboembolism: Retrospective Validation of the DAMOVES Score

Proceedings, 2018
Unprovoked venous thromboembolism is associated with a 5 to 27% annual risk of recurrence after discontinuation of anticoagulation, and indefinite anticoagulation is recommended if the bleeding risk is low to moderate.
A. I. Franco Moreno, M. J. García Navarro, C. L. De Ancos Aracil, A. Gimeno García, C. Montero Hernández, A. Villa Martínez, V. Piedrafita Mateo, J. Ortiz Sánchez, I. C. Sanz Acevedo, R. Martín Díaz, J. M. Ruiz Giardín   +10 more
doaj   +1 more source

Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases

British medical journal, 2019
Objective To assess the association between risk of venous thromboembolism and use of different types of hormone replacement therapy. Design Two nested case-control studies.
Y. Vinogradova, C. Coupland, J. Hippisley-Cox   +2 more
semanticscholar   +1 more source

Micellar Liquid Chromatography Determination of Edoxaban in Oral Solid Dosage Forms: Theoretical Aspects and Validation

ChemMedChem, EarlyView.
A method is developed and validated to quantify edoxaban in solid oral dosage forms using micellar liquid chromatography. A chemometric strategy is used to study the retention mechanism. The procedure is green, economic, safe, and easy to handle; offers high sample throughput; and is reliable, thus useful for pharmaceutical quality control.
Juan Peris‐Vicente, Devasish Bose, Rajendra‐Pasad Pawar, Abhilasha Durgbanshi, Samuel Carda‐Broch   +4 more
wiley   +1 more source

American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy.

Blood Advances, 2018
BACKGROUND Venous thromboembolism (VTE) complicates ∼1.2 of every 1000 deliveries. Despite these low absolute risks, pregnancy-associated VTE is a leading cause of maternal morbidity and mortality.
S. Bates, Anita Rajasekhar, S. Middeldorp, C. McLintock, M. Rodger, Andra H. James, S. Vazquez, I. Greer, J. Riva, Meha Bhatt, Nicole Schwab, D. Barrett, Andrea LaHaye, B. Rochwerg   +13 more
semanticscholar   +1 more source

Treatment of cancer‐associated venous thromboembolism: 12‐month outcomes of the placebo versus rivaroxaban randomization of the SELECT‐D Trial (SELECT‐D: 12m)

Journal of Thrombosis and Haemostasis, 2020
The Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism (SELECT‐D) trial demonstrated reduction in recurrent venous thromboembolism (VTE) but increased bleeding with rivaroxaban compared with dalteparin for
A. Marshall, M. Levine, C. Hill, Danielle Hale, Jenny Thirlwall, V. Wilkie, K. French, Ajay Kakkar, A. Lokare, A. Maraveyas, O. Chapman, A. Arif, S. Petrou, M. Maredza, F. Hobbs, J. Dunn, A. Young   +16 more
semanticscholar   +1 more source

Quantitative Model‐Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation

Clinical Pharmacology &Therapeutics, EarlyView.
Milvexian, an activated factor XI inhibitor, is being evaluated in the LIBREXIA phase III program for the prevention of thrombotic events, including in patients with atrial fibrillation (LIBREXIA AF). To guide the selection of a phase III dose regimen for LIBREXIA AF, two main approaches were used: (1) population pharmacokinetics and exposure–response ...
Wangda Zhou, Emily Bozenhardt, Gregory E. Alexander, Matthew L. Zierhut, Samira Merali, Antoinette Ajavon‐Hartmann, Peter Zannikos, Hyunmoon Back, EunYoung Suh, Navin Goyal, Mahesh N. Samtani, Alexei N. Plotnikov, Chandni Valiathan   +12 more
wiley   +1 more source